JPRN-jRCT2071260009 Pegcetacoplan Menopausal Vasomotor Symptoms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines JPRN-jRCT2071260009—A Phase 3, Multicenter, Single-arm Clinical Study to Assess the Safety and Tolerability of Intravitreal Administration of Pegcetacoplan in Japanese Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCT2071260009 is a hot trial to watch

Menopausal Vasomotor Symptoms is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. JPRN-jRCT2071260009 is notable because it tests Pegcetacoplan, Geographic Atrophy (Clearside), Gambogic acid in a Phase 3 design with AMDに伴うGAを有する日本人被験者を対象に、pegcetacoplanをIVT投与したときの安全性及び忍容性を評価する ・TEAE（治験薬投与後に発現した有害事象）及び重篤なTEAEの発現率及び重症度 as a primary decision variable. The wider PatSnap topic query returned 43 trial records and 78 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—AMDに伴うGAを有する日本人被験者を対象に、pegcetacoplanをIVT投与したときの安全性及び忍容性を評価する ・TEAE（治験薬投与後に発現した有害事象）及び重篤なTEAEの発現率及び重症度—determines what uncertainty this study can resolve. The reported time frame is Time frame not reported. Enrollment of 20 participants and geography in Japan shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• HIGHLIGHT 1: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor–positive breast cancer who are receiving adjuvant endocrine therapy. (Phase 3): TEAE(discontinuations due) = 2.0 % ; TEAE(discontinuations due) = 2.0 % .
• A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women (Phase 3): -; -; Baseline(Mean) = 16.16 Hot Flashes per day (Standard Deviation, 11.15); -; -.
• A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women (Phase 3): -; -; Baseline(Mean) = 14.26 Hot Flashes per day (Standard Deviation, 13.94); -; -.

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Pegcetacoplan (Approved; C3); Geographic Atrophy (Clearside) (Preclinical; target not reported); Gambogic acid (Preclinical; HSP90 x Tubulin).

Company & Deal Intelligence context: Apellis Pharmaceuticals, Inc. (APLS) — http://www.apellis.com.

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

JPRN-jRCT2071260009 is a focused lens on Menopausal Vasomotor Symptoms development. Its value will be determined by whether Pegcetacoplan can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.